Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Byoung Chul Cho

Showing results (1-10 of 452) with videos related to

Pageof 46
Sort By:
Clinical Lung Cancer|December 9, 2025
Response to the Letter to the Editor: "Lazertinib in EGFR-Mutated NSCLC with CNS Metastases: Reinforcing the Role of Third-Generation TKIs through Pooled Analysis"Byoung Chul Cho, YuKyung Kim
Yonsei Medical Journal|August 29, 2022
Lazertinib: on the Way to Its ThroneJiyun Lee, Min Hee Hong, Byoung Chul Cho
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2026
A Response to the Letter to the Editor: "Comment on COCOON: Daily 4% Chlorhexidine for Nail Care-Rationale, Safety, and Evidence Gaps"Byoung Chul Cho, Maxwell Sauder, Jairo Simoes, et al.
Nature Reviews. Clinical Oncology|July 18, 2025
Evolving roles of MET as a therapeutic target in NSCLC and beyondJii Bum Lee, Joo Sung Shim, Byoung Chul Cho
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 7, 2024
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLCSun Min Lim, Jii Bum Lee, Byoung Chul Cho
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?Chee-Seng Tan, Byoung Chul Cho, Ross A Soo
Cancer Research|January 5, 2022
Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung CancerSun Min Lim, Chang Gon Kim, Byoung Chul Cho
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancerChee-Seng Tan, Byoung-Chul Cho, Ross A Soo
The New England Journal of Medicine|February 25, 2026
Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. ReplyJames Chih-Hsin Yang, Seema Sethi, Byoung Chul Cho
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2021
Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?Chang Gon Kim, Byoung Chul Cho, Sun Min Lim
Pageof 46

Showing results (1-10 of 452) with videos related to

Sort By:
Pageof 46
Clinical Lung Cancer|December 9, 2025
Response to the Letter to the Editor: "Lazertinib in EGFR-Mutated NSCLC with CNS Metastases: Reinforcing the Role of Third-Generation TKIs through Pooled Analysis"Byoung Chul Cho, YuKyung Kim
Yonsei Medical Journal|August 29, 2022
Lazertinib: on the Way to Its ThroneJiyun Lee, Min Hee Hong, Byoung Chul Cho
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2026
A Response to the Letter to the Editor: "Comment on COCOON: Daily 4% Chlorhexidine for Nail Care-Rationale, Safety, and Evidence Gaps"Byoung Chul Cho, Maxwell Sauder, Jairo Simoes, et al.
Nature Reviews. Clinical Oncology|July 18, 2025
Evolving roles of MET as a therapeutic target in NSCLC and beyondJii Bum Lee, Joo Sung Shim, Byoung Chul Cho
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 7, 2024
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLCSun Min Lim, Jii Bum Lee, Byoung Chul Cho
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?Chee-Seng Tan, Byoung Chul Cho, Ross A Soo
Cancer Research|January 5, 2022
Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung CancerSun Min Lim, Chang Gon Kim, Byoung Chul Cho
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancerChee-Seng Tan, Byoung-Chul Cho, Ross A Soo
The New England Journal of Medicine|February 25, 2026
Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. ReplyJames Chih-Hsin Yang, Seema Sethi, Byoung Chul Cho
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2021
Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?Chang Gon Kim, Byoung Chul Cho, Sun Min Lim
Pageof 46